HIPEC in Ovarian Carcinoma Clinical Stage IIIC and IV During Interval Laparotomy

Ovarian cancer is the leading cause of gynecological cancer mortality, with no current screening method effective for early diagnosis, with 75% of advanced stage patients being detected. Not all patients are candidates for standard treatment, which is primary cytoreduction followed by adjuvant chemotherapy, due to the advanced process. A subgroup of patients will receive neoadjuvant chemotherapy followed by interval surgery, which allows higher rates of optimal cytoreduction with low morbidity and mortality. Hyperthermic intraperitoneal chemotherapy (HIPEC) is a therapeutic option that is used

Trial Details

NCT ID
NCT03275194
Phase
PHASE2
Sponsor
Instituto Nacional de Cancerologia de Mexico
Status
RECRUITING
Cancer Type
Ovarian Cancer
Interventions
  • HIPEC
Locations (sample)
  • Mexico City, Mexico|19.42847,-99.12766

Key Eligibility Criteria

  • Patients younger than 70 years
  • Patient with a diagnosis of high grade serous carcinoma of the ovary and low-grade endometrioid corroborated by histopathological study.
  • Clinical stage IIIC and IVA (cytology-positive pleural effusion) who have received induction chemotherapy 3 or 4 cycles of CARBOPLATIN and PACLITAXEL.
  • Partial response to treatment with chemotherapy and evaluated by computed tomography (RECIST-see below) and response of at least 50% by serum deter…

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Ovarian Cancer Trials on Trialify →